Inhibikase posts new corporate presentation highlighting PAH clinical program

Inhibikase Therapeutics, Inc.

New company presentation made available on investor relations website October 9, 2024.
Presentation focuses on clinical development of disease-modifying therapeutics for pulmonary arterial hypertension (PAH).
No specific financial results, trial data, or guidance disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.